Tirzepatide and pancreatitis risk: what the clinical evidence actually shows

What the MHRA's 2026 safety update actually said about GLP-1 medicines and the pancreas

The MHRA's Drug Safety Update of 29 January 2026 drew on post-marketing surveillance data accumulated since GLP-1 and dual GIP/GLP-1 medicines entered widespread clinical use. The regulator concluded that acute pancreatitis (inflammation of the pancreas) is an infrequent but recognised adverse effect across the class, tirzepatide included. The update did not restrict prescribing or change licence conditions; it reinforced existing SmPC labelling and asked prescribers and patients to be alert to the symptoms. That context matters. The signal is real, it has been formally assessed, and the outcome was a communication rather than a withdrawal. You can read the full update through the MHRA Drug Safety Update index, which archives all communications chronologically.

The mechanism behind the signal is not fully established, though researchers have proposed several routes: slowed gastric emptying may alter pancreatic enzyme dynamics; GIP and GLP-1 receptor activation may influence pancreatic secretion directly. What the data do not show is a strong, consistent dose-response relationship, meaning higher doses do not straightforwardly equal higher pancreatic risk in the clinical trial populations studied. That said, SURMOUNT-1 (the pivotal phase 3 trial that enrolled 2,539 adults) reported pancreatitis events at low absolute rates, consistent with the SmPC's "infrequent" classification. The NHS medicines page for tirzepatide lists pancreatitis among the side effects that require prompt medical attention.

For the people who do develop it, pancreatitis can be serious. Mild cases typically resolve with supportive care; severe cases carry risk of complications. The clinical imperative is to catch it early, which means knowing what to look for.

The symptoms that warrant urgent medical help

The symptom profile that should prompt same-day medical assessment is specific enough to be useful: severe, persistent pain in the upper abdomen or centre of the abdomen that spreads through to the back, often accompanied by nausea or vomiting and sometimes a fever. It does not settle with ordinary painkillers. It is typically constant rather than crampy. That pattern distinguishes pancreatitis from the much more common gastrointestinal side effects of tirzepatide (nausea, loose stools, belching, indigestion) which tend to come on after meals or dose changes, are usually mild-to-moderate, and generally settle within days to a couple of weeks of starting or increasing the dose.

If you develop that back-radiating abdominal pain while on tirzepatide, go to A&E or call 999 if the pain is severe. Do not wait for your next prescription review. If symptoms are less acute but still concerning, call 111. Our prescribers are available for aftercare queries seven days a week, but persistent abdominal pain that fits this pattern needs in-person clinical assessment, not a message in a portal. More detail on the full Mounjaro side-effect profile, including which symptoms are common versus which are rare, is covered on our Mounjaro side effects page.

Gallbladder problems (gallstones and cholecystitis) are a related area worth knowing about, because gallstone-related pain can sometimes trigger pancreatitis (gallstone pancreatitis), and GLP-1 medicines may affect gallbladder motility. Rapid weight loss of any cause also increases gallstone risk. Your prescriber factors this in when assessing your suitability for treatment.

Who carries the highest baseline risk, and how prescribers assess it

Certain factors raise an individual's background risk of pancreatitis independent of any medicine: a previous episode of pancreatitis (the strongest predictor of recurrence), active or symptomatic gallstones, very high blood triglycerides (hypertriglyceridaemia), and chronic heavy alcohol use. The Mounjaro SmPC lists a prior history of pancreatitis as a factor requiring careful consideration before prescribing, and our dedicated page on Mounjaro causing pancreatitis explains how that history shapes the prescriber's thinking in practice. This is one reason a thorough clinical history matters before any GLP-1 treatment starts, not a box-ticking exercise.

At nume, every consultation is read by a GPhC-registered Independent Prescriber the same day. A real clinician reviews your answers, not software running a rule tree. If your history includes any of the risk factors above, the prescriber will consider whether tirzepatide is appropriate, whether additional monitoring is sensible, or whether a different treatment pathway suits you better. Our clinical team's approach to this is outlined on the clinical team page. Wider context on the evidence base for tirzepatide in weight management is available on our Mounjaro overview page.

Transfer patients (people moving to nume from another provider) are asked for evidence of their current dose and treatment history precisely because continuity of clinical knowledge matters. A prescriber cannot make a well-informed safety judgement without it. If you have questions before starting a consultation, our FAQs cover what the process involves.

How to reduce the risk and report a concern

There is no reliably protective action that eliminates pancreatic risk on tirzepatide, but a few practical points reduce modifiable risk. Staying well hydrated, particularly during episodes of nausea or vomiting, limits the dehydration that can worsen any acute abdominal condition. Avoiding alcohol excess is sensible on treatment generally and specifically relevant here. Reporting any persistent abdominal pain early (rather than tolerating it hoping it passes) is probably the most useful thing a patient can do.

If you suspect a side effect, report it. The MHRA Yellow Card scheme is open to patients as well as healthcare professionals, and reports from people taking medicines in real-world conditions are a genuine source of post-marketing safety data. The scheme also accepts reports about suspect sellers, relevant context given the MHRA's ongoing enforcement action against counterfeit weight-loss pens circulating through unregulated online channels. Genuine tirzepatide from a GPhC-registered pharmacy arrives as a sealed KwikPen in temperature-controlled packaging; with nume, that means a DPD parcel tracked to your door, in plain unbranded packaging, with the pen itself holding the full remaining contents of your licensed prescription.

Separate pages go into more depth on specific aspects of this topic: our guidance on reducing pancreatitis risk on Mounjaro, the overall risk picture, and a focused look at whether Mounjaro can cause pancreatitis, including what the trial data shows. If you are considering treatment and want to discuss your personal history with a prescriber, the right starting point is a free consultation with our clinical team.